Targeting the primary tumor with optical probes, as reported in the current work using a high affinity and the very specific fluorescent-labeled anti-PSMA scFv, is, according to these preliminary preclinical results, a promising additional option. This evidence concerns the gene FOLH1 and neoplasm.